Analysis of the Lipid Profile and Atherogenic Risk during Androgen Deprivation Therapy in Prostate Cancer Patients
- 11 December 2012
- journal article
- research article
- Published by S. Karger AG in Urologia Internationalis
- Vol. 90 (1), 41-44
- https://doi.org/10.1159/000342814
Abstract
To analyse changes in lipid profiles observed in patients receiving androgen deprivation therapy (ADT) and to evaluate differences between medical castration and maximal androgen blockade (MAB). Serum levels of total cholesterol (TC), high-density lipoproteins (HDL), low-density lipoproteins (LDL) and triglycerides (TG) were prospectively evaluated in 33 patients with locally advanced or metastatic prostate cancer treated with ADT. The median age was 73.4 years. Serum lipids were measured at baseline and thereafter at 6 and 12 months. The modality of ADT was medical, with 3 months depot LHRH agonist, in 11 patients and MAB, by addition of 50 mg/day of bicalutamide, in 22 patients. TC increased from 210 to 227 mg/dl (p < 0.05), while LDL increased from 132 to 148 mg/dl (p < 0.05) at 6 months. There were no significant changes in HDL or TG levels. There were no significant differences in any of the analysed parameters after 12 months of ADT. The comparison between the group of patients treated with LHRH agonists alone and the group treated with MAB demonstrated no significant differences in any of the analysed parameters at 6 and 12 months (p > 0.05). Changes observed in TC and LDL after 6 months of ADT were transitory. No significant differences were observed according to the modality of ADT.Keywords
This publication has 14 references indexed in Scilit:
- Androgen-Deprivation Therapy in Prostate Cancer and Cardiovascular RiskCell Metabolism, 2010
- Diabetes and Cardiovascular Disease During Androgen Deprivation Therapy: Observational Study of Veterans With Prostate CancerJNCI Journal of the National Cancer Institute, 2009
- Association of Total Cholesterol/High‐Density Lipoprotein Cholesterol Ratio With Proximal Coronary Atherosclerosis Detected by Multislice Computed TomographyPreventive Cardiology, 2009
- Androgen deprivation therapy increases cardiovascular morbidity in men with prostate cancerCancer, 2007
- Lipoprotein profile in men with prostate cancer undergoing androgen deprivation therapyInternational Journal Of Impotence Research, 2006
- Testosterone suppression in men with prostate cancer leads to an increase in arterial stiffness and hyperinsulinaemiaClinical Science, 2003
- Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trialThe Lancet, 2002
- Changes in Body Composition during Androgen Deprivation Therapy for Prostate CancerJournal of Clinical Endocrinology & Metabolism, 2002
- Cause of death in men diagnosed with prostate carcinomaCancer, 1998
- Lipids, risk factors and ischaemic heart diseaseAtherosclerosis, 1996